More on CELC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $89.06 |
|
|||
| Open | $89.00 | ||||
| 52 Wk High | $0.00 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $92.85 | ||||
| Day Low | $88.64 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,161,861 | ||||
- Form 8-K Celcuity Inc. For: Aug 26
- Celcuity files sNDA for gedatolisib in PIK3CA mutant breast cancer
- Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
- Form 4 Celcuity Inc. For: Aug 14 Filed by: Laing Lance G.
- Form 4 Celcuity Inc. For: Aug 14 Filed by: Sullivan Brian F.
- Form 4 Celcuity Inc. For: Aug 14 Filed by: Hahne Vicky
- Celcuity Inc (CELC) PT Raised to $175 at Guggenheim
- H.C. Wainwright Reiterates Buy Rating on Celcuity Inc (CELC)
- Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
- Celcuity Inc (CELC) PT Lowered to $150 at Stifel as Gedatolisib Distribution Initiated
Entities mentioned with CELC
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
